Our use of cookies

We use necessary cookies to make our site work. We’d also like to set optional analytics cookies to help us improve it. We won’t set optional cookies unless you enable them. Using this tool will set a cookie on your device to remember your preferences.

For more detailed information about the cookies we use, see Privacy & Cookies

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in a way that does not directly identify anyone.


Back to all News

Imperial Brands Ventures Ltd announces investment in Oxford Cannabinoid Technologies

Imperial Brands Ventures Ltd, a subsidiary of Imperial Brands PLC, today announces that it has taken an equity stake in Oxford Cannabinoid Technologies (OCT).

OCT is a biopharmaceutical company focused on researching, developing, and licensing cannabinoid-based compounds and therapies. Its activities are licensed for operation by the UK Home Office.

Matthew Phillips, Chief Development Officer, Imperial Brands PLC said: “We are pleased to be partnering with OCT. Cannabinoid products have significant potential and our investment enables Imperial to support OCT’s important research while building a deeper understanding of the medical cannabis market.”


Notes to editors

Imperial Brands is a dynamic fast moving consumer goods company borne out of a strong tobacco heritage. We have continually evolved to embrace changing market dynamics and are increasingly focusing our attention on developing and expanding our portfolio of Next Generation Products.

Investor contacts   Media contacts  
Peter Durman +44 (0)7970 328 903 Alex Parsons +44 (0)7967 467 241
Matt Sharff +44 (0)117 933 7396 Simon Evans +44 (0)7967 467 684